Inefficacy of piracetam in the prevention of painful crises in children and adolescents with sickle cell disease

Acta Haematologica

Volumn 113, Issue 4, 2005, Pages 228-233

  Alvim, R C ^a   Viana, M B ^a,b   Pires, M A S ^a   Franklin, H M O H ^a   Paula, M J ^a   Brito, A C ^a   Oliveira, T F ^a   Rezende, P V ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b NONE   (Brazil)

Author keywords

Pain; Piracetam; Sickle cell disease

Indexed keywords

PIRACETAM; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; BEHAVIOR; CHILD; CLINICAL EXAMINATION; CLINICAL TRIAL; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; SICKLE CELL ANEMIA; SOCIAL PSYCHOLOGY; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PAIN; PIRACETAM; PLACEBOS; QUESTIONNAIRES;

EID: 21344435458     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084675     Document Type: Article

References (35)

1. Serjeant GR: Screening for sickle-cell disease in Brazil. Lancet 2000;356:168-169.
2. Paixão MC, Ferraz MHC, Januário JN, Viana MB, Lima JM: Reliability of isoelectrofocusing for the detection of Hb S, Hb C, and Hb D in a pioneering population-based program of newborn screening in Brazil. Hemoglobin 2001;25:297-303.
3. Bunn HF: Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997;337:762-769.
4. Serjeant GR, Serjeant BE: The painful crisis; in Sickle Cell Disease, ed 3. Oxford, Oxford University Press, 2001, pp 281-300.
5. Natarajan M, McIntire LV: Microvascular occlusion in sickle-cell anaemia. In: Pathophysiology and management of sickle cell pain crisis. Report of a Meeting of Physicians and Scientists, University of Texas Health Science Center at Houston, Texas. Lancet 1995;346:1408-1411.
6. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP: Mortality in sickle cell disease: Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-1644.
7. Fuggle P, Shand PAX, Gill LJ, Daves SC: Pain, quality of life and coping in sickle cell disease. Arch Dis Child 1996;75:199-203.
8. Williams I, Earles AN, Pack BB: Psychological considerations in sickle cell disease. Nurs Clin North Am 1983;18:215-229.
9. Silva CM, Viana MB: Growth deficits in children with sickle cell disease. Arch Med Res 2002;33:308-312.
10. Aluoch JR: The treatment of sickle cell disease: A historical and chronological literature review of the therapies applied since 1910. Trop Geogr Med 1984;36:1-26.
11. National Institute of Health: Management and Therapy of Sickle Cell Disease, ed 3. Bethesda, National Institute of Health, 1995, NIH Publ No 96-2117, pp 1-114.
12. de Montalembert M, Belloy M, Bernaudin F, Gouraud F, Capdeville R, Mardini R, Philippe N, Jais JP, Bardakdjian J, Ducrocq R, Maier-Redelsperger M, Elion J, Labie D, Girot R: Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease: The French Study Group on Sickle Cell Disease. J Pediatr Hematol Oncol 1997;19:313-318.
13. Murayama M: Biochemical and physicochemical alterations produced by piracetam on sickle cell blood. Proc Int Symp on Nootropic Drugs, Rio de Janeiro, Oct 1979, pp 205-210.
14. Araújo JT, Nero GS: Piracetam in sickle-cell anemia. Lancet 1977;ii:411.
15. Gini EK, Sonnet J: Use of piracetam improves sickle cell deformability in vitro and in vivo. J Clin Pathol 1987;40:99-102.
16. Nalbandian RM, Henry RL, Burek CL, Diglio CA, Goldman AI, Taylor GW, Hoffman WH: Diminished adherence of sickle erythrocytes to cultured vascular endothelium by piracetam. Am J Hematol 1983;15:147-151.
17. Asakura T, Ohnishi ST, Adachi K, Ozguc M, Hashimoto K, Devlin MT, Schwartz E: Effect of piracetam on sickle erythrocytes and sickle hemoglobin. Biochim Biophys Acta 1981;668:397-405.
18. Franklin IM: Piracetam and sickle-cell disease. Lancet 1980;i:767-768.
19. Stone PC, Chalder SM, Stuart J: Action of piracetam on cation flux and deformability of sickle cells. Clin Hemorheol 1988;8:779-790.
20. Costa FF, Zago MA, Bottura C: Effects of piracetam and iodoacetamida on erythrocyte sickling. Lancet 1979:ii:1302.
21. Riddington C, De Franceschi L: Drugs for preventing red blood cell dehydration in people with sickle cell disease. Cochrane Database Syst Rev. 2002;(4):CD003426.
22. el-Hazmi MA, Warsy AS, al-Fawaz I, Opawoye AO, Taleb HA, Howsawi Z, Mohamed AA, Aly AW, Refai S, Sugathan PS, Rab AS, Ahmed HB, Abulaban M, Abdulkader AM, Farid M: Piracetam is useful in the treatment of children with sickle cell disease. Acta Haematol 1996;96:221-226.
23. Sonnet J, Gini EK, Cornu G: Trial prevention of vaso-occlusive crises in homozygote sickle cell anemia using piracetam. Ann Soc Belge Méd Trop 1985;65:77-84.
24. Nalbandian RM, Henry RL, Murayama M: Sickle-cell disease: Two new therapeutic strategies. Lancet 1978;ii:570-571.
25. Mikatti MA, Solh HM, Deryan DE: A preliminary report on piracetam in sickle cell anemia: A double-blind cross-over clinical trial and effects on erythrocyte survival. King Faisal Spec Hosp Med J 1983;3:233-236.
26. Frank LS, Greenberg CS, Stevens B: Pain assessment in infants and children. Pediatr Clin North Am 2000;47:487-512.
27. Walco GA, Dampier CD: Pain in children and adolescents with sickle cell disease: A descriptive study. J Psychol 1990;15:643-658.
28. McGrath PA: An assessment of children's pain: A review of behavioral, physiological and direct scaling techniques. Pain 1987;31:147-176.
29. Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, Kinney TR: Pain in sickle cell disease: Rates and risk factors. N Engl J Med 1991;325:11-16.
30. Shapiro BS, Dinges DF, Orne EC, Bauer N, Reilly LB, Whitehouse WG, Ohene-Frempong K, Orne MT: Home management of sickle cell-related pain in children and adolescents: Natural history and impact on school attendance. Pain 1995;61:139-144.
31. Westerman MP, Bailey K, Freels S, Schlegel R, Williamson P: Assessment of painful episode frequency in sickle-cell disease. Am J Hematol 1997;54:183-188.
32. Nagel RL: Severity, pathobiology, epistatic effects and genetic markers in sickle cell anemia. Semin Hematol 1991;28:180-201.
33. American Academy of Pediatrics: Committee on Genetics. Health supervision for children with sickle cell diseases and their families. Pediatrics 1996;98:467-472.
34. Hillery CA: Potential therapeutic approaches for the treatment of vaso-occlusion in sickle cell disease. Curr Opin Hematol 1998;5:151-155.
35. Steinberg MH: Management of sickle cell disease. N Engl J Med 1999;340:1021-1030.